NYC launches study to see if lower mpox vaccine dose works for people with HIV
NCT ID NCT05654883
Summary
This study aims to understand how well a lower-dose mpox vaccine works and how safe it is for people living with HIV, compared to people without HIV and to the standard vaccine dose. Researchers will measure immune responses and track side effects in 174 participants who have received or plan to receive the mpox vaccine. The goal is to fill knowledge gaps and help guide public health recommendations for vaccinating people with HIV against mpox.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.